Payment overview · 2025
General Payments
$468.59
21 reported records · 10 companies
Healthcare provider profile · identity verified
John L Lokey, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · BRUNSWICK, GA · NPI 1124095542
Verified facts
What the public records show
CMS Open Payments records show John L Lokey, PA received $468.59 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $145.89 | 31.1% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $99.67 | 21.3% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.81 | 9.1% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $41.05 | 8.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $28.47 | 6.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.28 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.02 | 4.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.60 | 4.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.45 | 4.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.35 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $468.59 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.86 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $82.25 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.83 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $42.81 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $41.05 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $41.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $41.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $41.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.03 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $28.47 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 458 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 410 | 116 |
| Losartan Potassium | Losartan Potassium | 344 | 96 |
| Lisinopril | Lisinopril | 327 | 96 |
| Hydrochlorothiazide | Hydrochlorothiazide | 284 | 86 |
| Omeprazole | Omeprazole | 228 | 73 |
| Tramadol Hcl | Tramadol Hcl | 223 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 56 |
| Metformin Hcl | Metformin Hcl | 184 | 48 |
| Gabapentin | Gabapentin | 181 | 58 |
| Alprazolam | Alprazolam | 165 | 31 |
| Simvastatin | Simvastatin | 163 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 43 |
| Meloxicam | Meloxicam | 148 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 45 |
| Furosemide | Furosemide | 134 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 34 |
| Potassium Chloride | Potassium Chloride | 111 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 25 |
| Eliquis | Apixaban | 107 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 29 |
| Trazodone Hcl | Trazodone Hcl | 100 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 31 |
| Metformin Hcl Er | Metformin Hcl | 94 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 25 |
| Methylprednisolone | Methylprednisolone | 92 | 75 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 38 |
| Sertraline Hcl | Sertraline Hcl | 87 | 25 |
| Allopurinol | Allopurinol | 86 | 23 |
| Famotidine | Famotidine | 81 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 21 |
| Montelukast Sodium | Montelukast Sodium | 71 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 21 |
| Ozempic | Semaglutide | 70 | 14 |
| Clonazepam | Clonazepam | 68 | 13 |
| Glimepiride | Glimepiride | 68 | 18 |
| Cefdinir | Cefdinir | 67 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 64 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 19 |
| Estradiol | Estradiol | 60 | 17 |
| Spironolactone | Spironolactone | 59 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 18 |
| Prednisone | Prednisone | 54 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 13 |
| Alendronate Sodium | Alendronate Sodium | 53 | suppressed |
| Azithromycin | Azithromycin | 51 | 42 |
| Mounjaro | Tirzepatide | 51 | 11 |
| Atenolol | Atenolol | 50 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 15 |
| Glipizide Er | Glipizide | 47 | 16 |
| Bupropion Xl | Bupropion Hcl | 46 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 45 | 12 |
| Mirtazapine | Mirtazapine | 45 | 12 |
| Myrbetriq | Mirabegron | 45 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 14 |
| Baclofen | Baclofen | 43 | 11 |
| Fluconazole | Fluconazole | 43 | 32 |
| Testosterone Cypionate | Testosterone Cypionate | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Carvedilol | Carvedilol | 35 | 11 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 25 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 16 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Primidone | Primidone | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Colchicine | Colchicine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Zolmitriptan | Zolmitriptan | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $468.59 · 21 records | Novo Nordisk Inc | AREXVY, CHARTIS CATHETER, FREESTYLE LIBRE, General - Pain Management, INSPIRE, JARDIANCE, LINZESS, MOUNJARO, Ozempic, PULMONX CHARTIS TABLET CONSOLE, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, Wegovy, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error